Menu
← Oncology Approval Tracker
FDA DECISION ·
Keytruda + trastuzumab + chemotherapy
pembrolizumab with trastuzumab and fluoropyrimidine- and platinum-based chemotherapy · Merck
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
First-line therapy for locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma. The later traditional approval limits use to PD-L1 CPS of at least 1.
LAMPGEN ANALYSIS
Why it matters
The 2021 accelerated action combined checkpoint inhibition with HER2-directed treatment and chemotherapy. The 2025 conversion narrowed the biomarker population.
What research teams should watch
Preserve HER2, PD-L1 and treatment dates when comparing cohorts before and after the label changes.
PRIMARY RECORDS